Navigation Links
CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
Date:7/29/2008

estones ahead of schedule including initiation of the Phase II breast cancer trial and accelerated enrollment of patients into the Phase II melanoma trial," commented Dr. Tim Shannon, President and Chief Executive Officer of CuraGen. "Over the remainder of 2008, we look forward to completing enrollment in the melanoma study and subsequently presenting updated results during the fourth quarter of this year."

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the Company's revenue, expenses, depreciation, amortization, asset impairment charges, losses, income, and future cash and investment positions, including for the second half of 2008 and fiscal year 2008, the timing and expected results of our clinical programs, and the development and marketability of planned drugs, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such
'/>"/>

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
10. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Profil Institute for Clinical Research, ... and obesity, announced today a new textbook,  Translational Research ... by Springer, a leading global scientific publisher. ... illustrate techniques for use in early phase clinical studies ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( ... "Infectious Disease Diagnostics Market by Product, Application, Technology, End ... their offering. , The infectious disease diagnostics ... to reach $18,156.2 million by 2019 from $12,422.8 million ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has ... Allergen Source, Product & by End User - Global Forecast ... The global allergy diagnostics market is valued at $1,228.58 million ... of 12.67%, to reach $2,230.72 million by 2019. Allergy diagnostics ...
Breaking Medicine Technology:New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Puma Biotechnology, Inc., a development stage biopharmaceutical ... license the worldwide commercial rights to neratinib, a ... transduction through the epidermal growth factor receptors, ErbB1 ... is being studied in the neoadjuvant, adjuvant and ...
... Corp. (OTCQB: CYCA), leading the way to cost effective ... Erik Stephansen to President of its eHealth division.  Mr. ... part of the company,s recent launch of their CyttaConnect™ ... network and its partners, FDA approved Bluetooth medical devices. ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5New Leader for CyttaConnect™ Medical Monitoring eHealth Division 2New Leader for CyttaConnect™ Medical Monitoring eHealth Division 3
(Date:1/22/2015)... Calif. (PRWEB) January 22, 2015 ... Susan Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were ... their leadership in advancing biotechnology, biomedical science, medical ... and Olsen each received the “2014 Life Sciences ...
(Date:1/22/2015)... January 22, 2015 IsoComforter, Inc. has introduced ... with patented IsoTube design to treat specific body parts and ... most progressive and easy to use patented cold therapy machine ... sports related orthopedic and muscle injuries. IsoComforter has become ...
(Date:1/22/2015)... Payday lending practices in four southern ... financial distress to the states that permit them, according ... Center on Race and Wealth. , While they generate ... loans at the same time substantially depress economic activity, ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... component of overall health care gains momentum worldwide, Rev. ... York-based HealthCare Chaplaincy Network (HCCN), will be the ... advance spiritual care in Israel’s public health system. , The ...
(Date:1/22/2015)... 2015 Compare-autoinsurance.org has released a new blog post ... auto insurance policy . , Some types of vehicles ... check the newly released blog post to see if their vehicle ... damaged vehicles are some of the cars that cannot be covered ...
Breaking Medicine News(10 mins):Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... In celebration of,AARP,s 50th Anniversary and to ... throughout the nation, AARP today,announced the winners of ... more than $1 million nationally to support educational ... and foster,greater civic engagement among students and their ...
... it predicts major episodes, study finds , , WEDNESDAY, April ... young adults can increase their risk of developing depression, ... almost 600 young adults found that those with annual ... gradually increased over two decades, especially among women. In ...
... the extra health-care costs strain the system , , WEDNESDAY, April ... the chances of medical complications during pregnancy, but now a ... the health-care system. , Obese women who are pregnant tend ... more time with their doctors than normal-weight women do. Much ...
... an advance promising to dramatically reduce their dose of ... University School of Medicine in St. Louis have taken ... focused a powerful drug directly on tumors in rabbits ... 1,000 times lower than used previously for this purpose ...
... Arthur J.,Gallagher & Co. today announced the ... Florida. Terms of the transaction,were not disclosed., ... life insurance broker,that provides life insurance programs for ... specialize in arranging premium,financing of large life insurance ...
... To Be Part Of Live Auction At ADA,s ... Ritz-Carlton Dearborn, Donation By Chrysler Jeep Superstores Will Help Children And Teens Attend ... ... and education received a big boost thanks to the generous donation,of a two-year ...
Cached Medicine News:Health News:AARP Legacy Award Celebrates Seaford High School for Innovation in Education 2Health News:AARP Legacy Award Celebrates Seaford High School for Innovation in Education 3Health News:Persistent Insomnia Leads to Depression in Young Adults 2Health News:Obesity During Pregnancy Carries Bigger Price Tag 2Health News:Nano-sized technology has super-sized effect on tumors 2Health News:Nano-sized technology has super-sized effect on tumors 3Health News:Diabetes Research, Advocacy and Education Gets Big Boost with Donation of Two- Year Lease for 2008 Chrysler Sebring Convertible 2
... most potent, naturally secreted estrogen and is ... [1]. In the ovary, estradiol is produced ... less potent estrogen derived from androstenedione. Estrone ... tissues. In men, small amounts of estradiol ...
... has been useful in the differential diagnosis ... with chest pain. 18-20 ... of sensitive and specific biomarkers, such as ... kinase (CK-MB), and myoglobin, are increased in ...
The second-generation Dade Behring Acute Care Troponin I (cTnI) method is the first FDA cleared high sensitivity cTnI assay with the low-end precision necessary to meet the ESC/ACC guidelines (CV <10...
... The VITROS ECi brings true ... to immunodiagnostic testing. Highly sensitive assays ... oncology and bone metabolism testing are ... under development. The VITROS ECi can ...
Medicine Products: